

.....
(Original Signature of Member)

118TH CONGRESS
1ST SESSION

H. R. _____

To direct the Comptroller General of the United States to conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce certain medical countermeasures in the event of a public health emergency, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mr. LATTA introduced the following bill; which was referred to the Committee
on _____

A BILL

To direct the Comptroller General of the United States to conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce certain medical countermeasures in the event of a public health emergency, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Helping Evaluate Ap-
3 propriate Logistical Infrastructure for National Govern-
4 ment Response Act of 2023” or the “HEALING Response
5 Act of 2023”.

6 **SEC. 2. GAO REVIEW OF HHS EFFORTS TO ENSURE RAPID**
7 **PRODUCTION OF CERTAIN MEDICAL COUN-**
8 **TERMEASURES IN CASE OF A PUBLIC**
9 **HEALTH EMERGENCY.**

10 (a) IN GENERAL.—Not later than 1 year after the
11 date of the enactment of this Act, the Comptroller General
12 of the United States shall conduct and complete a review
13 examining the efforts of the Secretary of Health and
14 Human Services to ensure that the United States is pre-
15 pared to rapidly produce qualified countermeasures (as de-
16 fined in section 319F–1 of the Public Health Service Act
17 (42 U.S.C. 247d–6a)) in the event of a public health emer-
18 gency declared under section 319 of the Public Health
19 Service Act (42 U.S.C. 274d).

20 (b) CONTENTS.—The review conducted under sub-
21 section (a) shall include a review of—

22 (1) the efforts described in such subsection, in-
23 cluding the Secretary’s efforts to transition from the
24 Centers for Innovation and Advanced Drug Manu-
25 facturing program to any new efforts, including the

1 National Biopharmaceutical Manufacturing Partner-
2 ship and Industrial Base Expansion Connect;

3 (2) the progress made toward the implementa-
4 tion of such efforts; and

5 (3) the planning within the Department of
6 Health and Human Services to assess risks and
7 challenges associated with advanced development
8 and manufacturing of qualified countermeasures.

9 (c) REPORT TO CONGRESS.—Not later than 1 year
10 after completing the review under subsection (a), the
11 Comptroller General of the United States shall submit to
12 the Congress a report containing—

13 (1) the results of the review; and

14 (2) the Comptroller General’s recommendations
15 for ensuring that the United States is prepared to
16 rapidly produce qualified countermeasures in the
17 event of a public health emergency.